Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • IkT-001 for PAH
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts
May 14, 2025 4:05pm EDT

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

Apr 14, 2025 8:00am EDT

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mar 27, 2025 4:01pm EDT

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Feb 24, 2025 8:00am EST

Inhibikase Announces Expansion of Senior Leadership Team

Feb 18, 2025 8:00am EST

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

Nov 14, 2024 8:37am EST

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Oct 21, 2024 9:05am EDT

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 09, 2024 9:18am EDT

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Aug 14, 2024 4:25pm EDT

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 07, 2024 8:00am EDT

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2025 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap